Renaissance Technologies (RenTech)'s HAE Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 43,200 shares of Haemonetics Corporation (HAE) worth $2.43 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in HAE, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2018, adding 650,200 shares. Largest reduction occurred in Q2 2021, reducing 679,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +43,200 | New Buy | 43,200 | $56.36 |
| Q4 2024 | -42,000 | Sold Out | 0 | $0.00 |
| Q3 2024 | -13,500 | Reduce 24.32% | 42,000 | $80.38 |
| Q2 2024 | +55,500 | New Buy | 55,500 | $82.73 |
| Q1 2024 | -38,500 | Sold Out | 0 | $0.00 |
| Q4 2023 | -103,800 | Reduce 72.94% | 38,500 | $85.51 |
| Q3 2023 | +70,900 | Add 99.30% | 142,300 | $89.58 |
| Q2 2023 | +66,200 | Add 1273.08% | 71,400 | $0.09 |
| Q1 2023 | +2,000 | Add 62.50% | 5,200 | $0.08 |
| Q4 2022 | +3,200 | New Buy | 3,200 | $0.08 |
| Q3 2022 | -40,100 | Sold Out | 0 | $0.00 |
| Q2 2022 | +18,000 | Add 81.45% | 40,100 | $65.19 |
| Q1 2022 | +22,100 | New Buy | 22,100 | $63.21 |
| Q4 2021 | -129,785 | Sold Out | 0 | $0.00 |
| Q3 2021 | -470,709 | Reduce 78.39% | 129,785 | $70.59 |
| Q2 2021 | -679,600 | Reduce 53.09% | 600,494 | $66.64 |
| Q1 2021 | -296,100 | Reduce 18.79% | 1.28 M | $111.01 |
| Q4 2020 | -357,991 | Reduce 18.51% | 1.58 M | $118.75 |
| Q3 2020 | -253,600 | Reduce 11.59% | 1.93 M | $87.25 |
| Q2 2020 | +3,400 | Add 0.16% | 2.19 M | $89.56 |
| Q1 2020 | -255,431 | Reduce 10.47% | 2.18 M | $99.66 |
| Q4 2019 | -187,084 | Reduce 7.12% | 2.44 M | $114.90 |
| Q3 2019 | +142,500 | Add 5.74% | 2.63 M | $126.14 |
| Q2 2019 | +108,700 | Add 4.58% | 2.48 M | $120.34 |
| Q1 2019 | -43,900 | Reduce 1.81% | 2.38 M | $87.48 |
| Q4 2018 | +163,100 | Add 7.23% | 2.42 M | $100.05 |
| Q3 2018 | +286,800 | Add 14.56% | 2.26 M | $114.58 |
| Q2 2018 | +650,200 | Add 49.28% | 1.97 M | $89.68 |
| Q1 2018 | +342,400 | Add 35.04% | 1.32 M | $73.16 |
| Q4 2017 | +100,893 | Add 11.51% | 977,100 | $58.08 |
| Q3 2017 | -43,593 | Reduce 4.74% | 876,207 | $44.87 |
| Q2 2017 | +101,200 | Add 12.36% | 919,800 | $39.49 |
| Q1 2017 | -76,600 | Reduce 8.56% | 818,600 | $40.57 |
| Q4 2016 | +11,600 | Add 1.31% | 895,200 | $40.20 |
| Q3 2016 | +106,300 | Add 13.68% | 883,600 | $36.21 |
| Q2 2016 | +500,100 | Add 180.41% | 777,300 | $28.99 |
| Q1 2016 | +87,500 | Add 46.13% | 277,200 | $34.98 |
| Q4 2015 | -70,300 | Reduce 27.04% | 189,700 | $32.24 |
| Q3 2015 | +213,700 | Add 461.56% | 260,000 | $32.32 |
| Q2 2015 | -38,000 | Reduce 45.08% | 46,300 | $41.36 |
| Q1 2015 | -16,100 | Reduce 16.04% | 84,300 | $44.92 |
| Q4 2014 | +63,700 | Add 173.57% | 100,400 | $37.42 |
| Q3 2014 | -178,100 | Reduce 82.91% | 36,700 | $34.93 |
| Q2 2014 | -39,426 | Reduce 15.51% | 214,800 | $35.28 |
| Q1 2014 | +228,126 | Add 874.05% | 254,226 | $32.59 |
| Q4 2013 | -211,400 | Reduce 89.01% | 26,100 | $42.15 |
| Q3 2013 | +3,600 | Add 1.54% | 237,500 | $39.88 |
| Q2 2013 | +233,900 | Add 0.00% | 233,900 | $41.35 |
Renaissance Technologies (RenTech)'s Haemonetics Corporation Investment FAQs
Renaissance Technologies (RenTech) first purchased Haemonetics Corporation (HAE) in Q2 2013, acquiring 233,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Haemonetics Corporation (HAE) for 48 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Haemonetics Corporation (HAE) was in Q2 2018, adding 1,969,700 shares worth $176.64 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 43,200 shares of Haemonetics Corporation (HAE), valued at approximately $2.43 M.
As of the Q1 2026 filing, Haemonetics Corporation (HAE) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Haemonetics Corporation (HAE) was 2,626,900 shares, as reported at the end of Q3 2019.